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Proliferative Responses of the Skin to
External Stimuli
by Friedrich Marks1 and Gerhard Furstenberger1
The skin, in particular the epidermis, offers unique opportunities to investigate the induction
and control ofcellular proliferation and tissue homeostasis both under in vivo and in vitro con-
ditions. Moreover, it represents one ofthe most feasible model systems for experimental cancer
research. As the primary border of the body, the skin has important protective and defensive
functions. A general response to external injury consists of a thickening of the epithelial layer
(epidermal hyperplasia) combined with an inflammatory reaction. This hyperplastic transfor-
mation ofthe skin is a critical condition ofskin tumor development (i.e., conversion and promo-
tion) and of the wound response. It is believed to be due to a transformation of keratinocytes
into an activated state characterized by an increased rate of proliferation and the ability to
release a series ofgrowth factors and other cytokines that coordinate the defense reaction (e.g.,
hyperproliferation, recruitment of leukocytes, activation of the immune system) along auto-
and paracrine feedback loops. The initial and probably later phases of this response depend
critically on a local release of eicosanoids such as prostaglandins and lipoxygenase-generated
factors. A unique reaction seen upon phorbol ester treatment of mouse skin is a strong induc-
tion of the enzyme 8-lipoxygenase, which might be involved in skin tumor development by cat-
alyzing the generation ofclastogenic metabolites thought to play a role in the conversion stage.
Hyperplasia may be considered to be the result of an imbalance between the rates of cell gain
and cell loss. Therefore, hyperplastic transformation has to be distinguished from another
response of skin to external stimuli where the homeostatic equilibrium is maintained (i.e., no
hyperplasia develops in spite ofstronghyperproliferation). This balanced hyperproliferation as
induced by mild stimuli (pressure, phorbol ester 4-O-methyl-TPA) is neither accompanied by
inflammatory reactions norby the symptoms ofkeratinocyte activation. It may simply be due to
an increased rate ofcell-cycle traverse in the proliferative tissue compartment. In contrast, the
prostaglandin-dependent activation of keratinocytes leading to hyperplastic transformation
resembles in many aspects (such as, for instance, the activation ofcell -cycle-related genes) the
Go-S transition ofcells in vitro. The control ofproliferative homeostasis in normal epidermis is
an unresolved problem. It is not known whether the rate of cell proliferation adapts automati-
cally to the rate of terminal differentiation or whether this adaption is regulated by local fac-
tors such as the elusive chalones or other inhibitory signals like transforming growth factor [B.
The same is true for stimulatory growth factors such as epidermal growth factor and transform-
ing growth factor-a whose fimction may be that ofwound hormones rather than ofhomeostatic
regulators ofnormal tissue regeneration.
Introduction
The beautiful smooth surface ofhuman skin suggests
simplicity, but it covers one of the most complex and
most reactive organs, which as an outer shield of the
body, is destined to interact and cope with the environ-
ment. The skin performs its functions by means of a
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highly sophisticated communication network between
different compartments and cell types (e.g., epidermis,
dermis, blood vessels, sweat and sebaceous glands,
nerves, immunocompetent cells, invading leukocytes.
At the same time, these interactions provide the very
conditions for skin tumordevelopment.
Skin Tumorigenesis and Cell
Proliferation
The skin offers one of the most suitable and best
characterized models for investigating the mechanisms
of carcinogenesis, in particular the relationship
between cell proliferation and tumor development. It
has been known for a long time that under certainMARKS AND FURSTENBERGER
experimental conditions, initiation (the initial muta-
genic event oftumorigenesis) may result in a life-long
state of latency that is lifted only by a massive induc-
tion ofcellular proliferation, for instance by wounding,
UV irradiation, or application of irritating chemicals.
This phenomenon is called tumor promotion. In skin,
the induction ofcellular hyperproliferation cannot only
overcome the latency of cancer but also the latency of
other genetically determined diseases such as eczema,
psoriasis (Kobner phenomenon), and common warts.
Vice versa, tumor promotion by wounding has also
been reported for many other tissues, even including
plants where crown gall tumorigenesis due to bacterial
infection is promoted by wounding. Thus, the induction
ofcellular proliferation, in particular in the course of a
wound response, may provide a general mechanism by
which genetically determined but latent hyperprolifer-
ative states can be expressed (1).
While healthy tissue returns to normal after some
time, in certain skin diseases the hyperproliferative
state, once induced, continues endlessly, probably due
to self-perpetuation. Thus, the mechanism of termina-
tion rather than induction may be defective. It has
been said that a tumor resembles a wound that does
not heal or that a would resembles a tumor that heals
itself(2,3).
Hyperproliferation and Hyperplasia
Starting from a naive point ofview, one would expect
any hyperproliferation to result in hyperplasia, i.e., in
an increase ofcell number and tissue mass. In an intact
tissue, however, the rate ofcell gain is generally closely
coupled to the rate ofcell decay, thus guaranteeing the
stability of tissue mass and function in spite of great
fluctuations in the rates ofcellular proliferation and cell
death. The homeostatic control mechanisms are myste-
rious. As long as these mechanisms are working prop-
erly, any increase ofcell gain will be precisely matched
by a corresponding increase of cell loss and vice versa;
in other words, no hyperplasia will develop even in the
case of strong hyperproliferation; the hyperprolifera-
tive state willremain balanced (Fig. 1).
A demonstration ofbalanced hyperproliferation may
be taken as proofofthe existence ofapowerful homeo-
static control device in a given tissue. About 15 years
ago, we were able to show balanced hyperproliferation
in epidermis in vivo, for example, after mild mechani-
cal stimulation (pressure, massage) or application of
the phorbol ester 4-0 methyl 12-tetradecanoyl-phorbol
13-acetate [4-0-MeTPA (4)].
The significance of such an observation becomes
especially evident when comparing the results obtained
with apparently closely related stimuli (such as mechan-
ical removal of the horny layer (versus massage) and
application of the phorbol ester tumor promoter TPA
(versus 4-0-MeTPA). Both stimuli induce an unbal-
anced hyperproliferation in the epidermis, which
results in pronounced hyperplasia, although the hyper-
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FIGURE 1. The difference between hyperproliferation and hyperpla-
sia. In permanently regenerating tissues such as the epidermis a
steady state between the rate of cell gain and the rate ofcell loss
guarantees the constancy oftissue mass and function (symbolized
by the shaded circle). As long as this steady state remains intact,
any increase in the rate of cell gain (hyperproliferation) will be
automatically matched by a corresponding increase of the rate of
cell loss: the hyperproliferative state is balanced. Hyperplasia
results from unbalanced hyperproliferation due to weakening or
impairment ofthe steady-state control. From Marks (4).
proliferative response (mitotic rate) to these com-
pounds is by no means stronger than the response to
massage or4-0-MeTPA application.
This result clearly shows that hyperplasia is not due
to an overshooting of cellular proliferation but that
there must be fundamental, qualitative differences
between the balanced and unbalanced hyperprolifera-
tive response. Indeed, hyperplastic development is
accompanied by cellular and molecular events that are
not seen upon induction ofbalanced hyperproliferation
(4). These include inflammatory reactions, mediator
release from keratinocytes (for instance, eicosanoids),
formation of autocrine feedback loops, activation of
cell-cycle-related genes such as c-fos, c-myc, ornithine
decarboxylase, transforming growth factor-[ (TGF,),
and others, and down regulation of growth inhibitory
pathways, such as those for glucocorticoids, and -
adrenergic agonists.
Thus, it appears as if balanced hyperproliferation is
just due to an acceleration of the cell-cycle traverse in
the proliferative tissue compartment, whereas hyper-
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plasia results from an entry ofspare cells into the cycle,
somehow resembling the GO-S transition in vitro.
These observations prompted us (5) to put forward the
concept of"hyperplastic transformation." By using this
term, we wanted to distinguish the hyperplastic-
inflammatory response from ordinary balanced hyper-
proliferation.
Hyperplastic Transformation and
Tumor Promotion
Tumor promotion has been shown to depend critical-
ly on repeated hyperplastic transformation, resulting
in sustained epidermal hyperplasia (6,7). Hence, it is
this kind ofhyperproliferative response that is closely
related to skin carcinogenesis. It must not be over-
looked, however, that sustained hyperplasia may only
be a necessary but not a sufficient condition of tumor
development in initiated skin, since there are agents
and manipulations that act as strong hyperplastic
transformants but do not induce tumor development.
Stripping the horny layer is such a manipulation (8),
whereas deep skin wounding provides, upon initiation,
a strong stimulus for tumor development (1). Another
example is provided by the phorbol ester of retinoic
acid (RPA) (9) or the plant poison mezereine (10), which
have been called incomplete tumor promoters because
they induce papilloma development in initiated mouse
skin only upon short-term pretreatment of the tissue
with a complete promoter such as TPA or wounding.
Such observations gave rise to the concept of two-
stage promotion or conversion-promotion, which
means that for the induction of tumor development, in
addition to hyperplastic transformation, manipulation
is required to convert the initiated skin into a pro-
motable state [i.e., render it susceptible to the promot-
ing effect of continuous hyperplastic stimulation (Fig.
2). Thus, the well-established relationship between
sustained epidermal hyperplasia and skin tumor pro-
motion seems to be valid only for stage 2 ofpromotion.
In contrast, the nature of stage 1 (conversion) is still
not entirely clear. Conversion has been shown to
depend on the induction of epidermal DNA synthesis,
to correlate with chromosomal damage, to be effective
either before or after initiation, and to result in a
rather long-lasting alteration recognizable as promota-
bility. Moreover, conversion depends on the local
release of lipoxygenase-generated arachidonic acid
(AA) metabolites, which may act as clastogenic media-
tors (11,12). Finally, conversion can be evoked not only
by complete promoters such as TPA or by wounding
but also by an intracutaneous injection of a mixture of
TGFa and TGFO, two established wound hormones.
The latter observation is particularly intriguingbecause
these two cytokines exhibit antagonistic effects of ker-
atinocyte proliferation in vitro (i.e., activation by TGFa
and inhibition by TGF,). For more details and an in-
depth discussion of mechanistic aspects of conversion,
see Marks and Furstenberger (13).
The Activated Keratinocyte
Only recently has experimental dermatology given
scope for the theory ofhyperplastic transformation by
putting forward the concept of the activated ker-
atinocyte (14), which is essentially the cellular counter-
part of the more functional concept of hyperplastic
transformation. The concept of the activated ker-
atinocyte is the result ofthe rather dramatic change in
our view ofthis cell type. Until about 1980, the epider-
mis was considered to provide mainly a resistant,
horny layer protecting the body from injury and water
loss. In recent years, we have learned, however, that
the keratinocyte has many more physiological func-
tions. Together with other skin cells (for instance the
antigen-presenting Langerhans cells), the keratinocyte
is not only the body's most advanced outpost, but it
occupies a central position as a signaling interface
between the surrounding environment and the body
(15). The keratinocyte is able to translate a wide vari-
ety of harmful environmental stimuli into endogenous
signals, which then activate the defense mechanisms of
the body. These include attraction and activation of
leukocytes and lymphocytes, activation ofthe immune
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FIGURE 2. The stages of experimental carcinogenesis in mouse skin. Under proper experimental conditions, initiation will not result in tumor
development unless additional nonmutagenic manipulations (conversion and promotion) are carried out. The initiation-conversion-promotion
approach of skin carcinogenesis results primarily in papillomas, some ofwhich develop into carcinomas. This malignant progression can be
enhanced by increasing the dose ofthe initiator orby treating the papillomas with a mutagenic carcinogen. From Marks and Furstenberger
(36).
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system, effects on blood flow, coagulation, and the
complement system, as well as on epidermal cell prolif-
eration.
These responses are controlled by a complex cocktail
of mediators and cytokines released from epidermal
cells and other skin compartments (Fig. 3). Unstim-
ulated epidermis produces such factors only at very
low doses or has sequestered them in an inactive state.
Upon exogenous stimulation, mediator and cytokine
production are strongly induced; in other words, the
resting keratinocyte becomes an activated one. The
visible result ofthis activation is hyperplastic transfor-
mation.
Thus, the main characteristic of the activated ker-
atinocyte is its ability to express and release, upon
stimulation, cytokines and eicosanoids and to express
the corresponding receptors together with cell adhe-
sion molecules such as I-CAM-1 (16). Many of these
cytokines, such as TGFa, TGFP, interleukin-1 (IL-1),
and others, are subject to autoinduction, thus provid-
ing a strong autocrine amplification mechanism
(1,14,17). In addition, cytokines may induce each other,
for example IL-1 and TGFa (18), or stimulate the pro-
duction ofother mediators such as the eicosanoids [IL-
1, TGFa, bradykinine and others (19,20)].
The effects of cytokines released from the activated
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keratinocyte are manifold. They may be grouped into
the following categories: a) mitogenic activation ofthe
keratinocyte, as has been shown for TGFa, bFGF (basic
fibroblast growth factor), IL-1, IL-3 and others, or inhi-
bition, as by tumor necrosis factor (TNFa), INFy
(interferon gamma), catecholamines, and chalones
(1,21); b) recruitment of the cells of the inflammatory
infiltrate and of T-lymphocytes, as accomplished by
IL-1, IL-6, IL-8, PDGF (platelet-derived growth fac-
tor, leukotriene B4 (LTB4), and 12-HETE (hydroxy
eicosatetraenoic acid) (14,18,19,22); c) effects on blood
vessels and connective tissue such as fibrosis, angio-
genesis, and remodeling ofthe extracellular matrix, as
induced by TGFf, PDGF, bFGF, TGFa, epidermal
growth factor (EGF) (23).
The cells of the inflammatory infiltrate as well as
various nonepidermal cells residing in skin are also
producers of cytokines, many of which may act on the
keratinocyte. Thus, upon external stimulation, a com-
plex cytokine network rapidly develops between the
different compartments ofthe injured tissue. This net-
work integrates the functions ofthe various cell types
involved in defense and tissue repair. Both induction of
an inflammatory infiltrate and the effects on dermis
and blood vessels give rise to the formation ofgranula-
tion tissue or, in the case of carcinogenesis, to the so-
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FIGURE 3. Hyperplastic transformation ofskin as the result ofkeratinocyte activation. Upon irritation or injury ofskin, the keratinocytes pro-
duce and secrete a complex cocktail oflipid mediators and cytokines. These factors recruit and activate other cell types involved in repair
and defense processes, emitting their own chemical signals (right). Many ofthese factors act on the keratinocytes, where, together with ker-
atinocyte-derived factors they control cell proliferation along para- and autocrine mechanisms: (+) stimulation: (-) inhibition.
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called stroma reaction, which is a critical condition of
tumor growth (2,13,24).
One important aspect of the network appears to be
the interaction between keratinocytes and T-lympho-
cytes (16,25). This interaction is made possible by the
release of T-cell-attracting signals such as IL-8 from
keratinocytes and by the expression of I-CAM-1 on
keratinocytes and ofthe corresponding integrin LFA-1
on T-cells.
The interaction is thought to lead to intense cytokine
cross-talk between these two cell types. Moreover, it
brings T-cells into the vicinity of the antigen-present-
ing Langerhans cells. As far as chronic hyperprolifera-
tion is concerned, it has been suggested that defects in
the keratinocyte-T-cell interaction may be causally
related to hyperproliferative diseases such as psoriasis
and other dermatoses (25) and even cancer. Although
cytotoxic T-cells have been shown to be capable of
lysing keratinocytes via LFA-1-I-CAM-1 recognition,
basal cell carcinoma cells do not express I-CAM-1, thus
perhaps escaping immunosurveillance (25).
The Hierarchy of the Epidermal
Cytokine Network
An important question is whether some sort of hier-
archy exists in the cutaneous cytokine network. As
mentioned before, most cytokines are not found in the
resting keratinocyte but are induced only upon injury.
Such induction processes may take hours or days, so
that the corresponding factors cannot be considered as
triggering signals.
There are, however, a few exceptions to this rule,
and they may be of great importance. They include
bFGF, TGF3, IL-la, and the eicosanoids, which are all
found in unstimulated keratinocytes, but probably in
an inactive form, either as precursors as TGF, or
trapped by the extracellular matrix as bFGF, seques-
tered inside the cell as IL-1 or the eicosanoids (in the
form of a protein precursor or as phospholipid-bound
arachidonic acid). In each case there is evidence that
these inactive mediators are activated and released
immediately upon wounding or irritation.
TGFP1 has been immunologically demonstrated in
the suprabasal cell layers of normal human (26) and
mouse epidermis (27). In an elegant study, Kane et al.
(26) recently provided immunological evidence that
skin expresses an inactive TGFO-precursor, which is
proteolytically activated and released immediately
upon injury. Later on, this is followed by de novo syn-
thesis of TGFP3-mRNA. In skin, TGF,B has three
major effects (28,29): it inhibits keratinocyte prolifera-
tion, it remodels the intracellular matrix, resulting in
the induction ofkeratinocyte migration, and it attracts
white blood cells and induces angiogenesis. Thus,
TGF3 may play an important role in the wound
response (30), in particular in the covering of the
wound by migration of epithelial cells and in the stro-
ma reaction by formation ofgranulation tissue. TGF,-
induced keratinocyte migration may result in an
impoverishment of epithelial cells in the vicinity of the
wound, resulting in compensatory hyperproliferation,
probably enhanced by additional wound hormones such
as TGFa, which may overcome the antiproliferative
activity ofTGFf at these sites.
Like TGFI, IL-1 is also a multifunctional cytokine,
although with a different spectrum of functions (31).
IL-ia is trapped inside the keratinocyte in unusually
large amounts (14). Because it does not possess any-
thing like a signal peptide sequence, there is no way of
ascertaining as yet how it can be released except for
cell destruction. This is the central point in the concept
ofkeratinocyte activation where IL-loc is actually pro-
posed to play the key role (14).
Our group has put forward the idea of eicosanoids
playing a central role in keratinocyte activation (19,20).
This concept is based on the observation that the for-
mation of prostaglandin E2 (PGE2) transiently occur-
ring in mouse epidermis immediately after stimulation
by a hyperplastic transformant (irritant, wounding,
etc.) is critical for the development ofepidermal hyper-
plasia in vivo, whereas the accompanying inflammato-
ry reaction is controlled by lipoxygenase-generated
arachidonic acid metabolites.
Indeed, 12-HETE and LTB4 have both been shown
to have strong leukotactic activity and to induce
hyperplastic transformation of skin when injected
intracutaneously (19,20). The most abundant arachi-
donic acid metabolite found in hyperplastically trans-
formed mouse skin (at least upon treatment with the
phorbol ester TPA) is 8-HETE (19,20). The corre-
sponding enzyme 8-lipoxygenase is almost absent in
resting epidermis but strongly induced upon treatment
with the tumor promoter. The physiological role of 8-
HETE and related metabolites is unknown. In the
course ofskin tumor development, 8-lipoxygenase may
provide clastogenic arachidonic acid metabolites,
inducing chromosomal damage (12), which is thought
to be involved in the conversion stage (see above).
The induction of the eicosanoid cascade in skin is a
general response to all kinds of irritants, irradiation,
and mechanical wounding. Eicosanoid formation in
keratinocytes has also been shown to be induced by
wound factors such as EGF, TGFa, IL-1, bradykinin,
histamine, thrombin, bFGF, and probably many oth-
ers. Phospholipase A2, the key enzyme of eicosanoid
production in keratinocytes, has been found to be acti-
vated along multiple pathways of intracellular signal
transduction (Fig. 4).
Because IL-1 is an inducer ofthe eicosanoid cascade
in keratinocytes (32), our concept may well fit the idea
that IL-1 provides one of the first signals in ker-
atinocyte activation (14). On the other hand, the
release of eicosanoids along IL-1-independent routes
may explain why hyperplastic transformation is
induced by agents that probably do not destroy ker-
atinocytes, which is thought to be prerequisite for IL-1
liberation.
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FIGURE 4. Multiple pathways of phospholipase A2 activation (i.e.,
induction ofthe eicosanoid cascade) in keratinocytes.
Mechanisms of Keratinocyte
Activation
The extremely complex interactions within the cuta-
neous cytokine network indicate that there are various
pathways rather than one master key for keratinocyte
activation. Thus, the destruction of epidermal cells
may result in the release ofpreformed mediators such
as IL-1, which then trigger the response, whereas pri-
mary wound factors such as thrombin, PAF (platelet-
activating factor), adenosine nucleotides, kinins, and
complement factors may be released from nonepider-
mal sources and interact with keratinocytes along the
physiological pathways ofintracellular signal transduc-
tion (Fig. 3). Finally, a direct interaction of exogenous
stimuli with the cellular elements of signal transduc-
tion (for instance, protein kinase C in the case of the
phorbol ester tumor promoters) may be envisaged. All
these interactions may lead to keratinocyte activation
and, as a secondary consequence, to the destruction of
keratinocytes, for instance through the release of
active oxygen radicals from invading leukocytes.
Considering the close relationship between hyperplas-
tic transformation and tumor development, it may be
postulated that tumor promotion can be induced either
bynonspecific damage such as mechanical wounding or
by more specific interactions with intercellular signal-
ing and intracellular signal transduction. Indeed,
destructive manipulations such as wounding (1) or
application of cytotoxic agents (33,34) exert a tumor-
promoting effect just like protein kinase C activators
(phorbol esters) or inhibitors of protein phosphatases
[okadaic acid (33)]. Moreover, cytokine injection into
initiated mouse skin exhibits a substantial tumor-pro-
moting effect, as we have recently shown for TGFa
plus TGFf (35). In any case, the common denominator
seems to be that keratinocyte activation results in
hyperplastic transformation, and hence, there seems to
be a direct relationship in skin between tumor develop-
ment and the wound response.
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